secwatch.observer — SEC 8-K summary
======================================

Issuer:     NKGen Biotech, Inc. (—)
CIK:        0001845459
Form:       8-K
Filed at:   2024-10-04T23:59:59+00:00
Accession:  0001213900-24-085185
Event type: leadership
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

NKGen Biotech appoints Michael Klowden and Kathleen Scott as directors
----------------------------------------------------------------------

- Michael Klowden appointed Class II director until 2025 annual meeting; also joins Audit and Compensation Committees and chairs N&CG Committee.
- Kathleen Scott appointed Class III director until 2026 annual meeting; chairs Audit and Compensation Committees and serves on N&CG Committee.
- Both directors will receive deferred non-employee director compensation, paid when Company meets funding goals.
- No arrangements or related transactions exist between new directors and Company per Reg S-K Item 404(a).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1845459/000121390024085185/0001213900-24-085185-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1845459/000121390024085185/ea0216761-8k_nkgen.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-085185

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer